Clinicopathological features of triple-negative breast cancer in Taiwanese women

International Journal of Clinical Oncology

Volumn 16, Issue 5, 2011, Pages 500-505

  Yao Lung, Kuo ^a   Dar Ren, Chen ^b   Tsai Wang, Chang ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

Prognosis; Taiwan; Triple negative breast cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; HER2 PROTEIN, HUMAN;

AGE DISTRIBUTION; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TAIWAN; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; UNIVARIATE ANALYSIS; ADULT; AGED; BREAST TUMOR; LYMPH NODE; METABOLISM; MORTALITY; PATHOLOGY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TAIWAN;

EID: 84857098861     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0211-9     Document Type: Article

References (24)

1. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137-2150 (Pubitemid 46655601)
2. Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235-244 (Pubitemid 46291713)
3. Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312 (Pubitemid 350232263)
4. Rhee J, Han SW, Oh DY et al (2008) The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 8:307
5. Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434 (Pubitemid 47219710)
6. Lund MJ, Trivers KF, Porter PL et al (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 113:357-370
7. Lin C, Chien SY, Chen LS et al (2009) Triple negative breast carcinoma is a prognostic factor in Taiwanese women. BMC Cancer 9:192
8. Cunningham JE, Montero AJ, Garrett-Mayer E et al (2009) Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes Control 21:399-409
9. Trivers KF, Lund MJ, Porter PL et al (2009) The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 20:1071-1082
10. Brower V (2009) Search for new treatments intensifies for triplenegative breast cancer. J Natl Cancer Inst 101:1536-1537
11. Woodward WA, Strom EA, Tucker SL et al (2003) Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol 21:3244-3248 (Pubitemid 46606256)
12. Singletary SE, Greene FL (2003) Revision of breast cancer staging: the 6th edition of the TNM Classification. Semin Surg Oncol 21:53-59 (Pubitemid 37127474)
13. Singletary SE, Allred C, Ashley P et al (2003) Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 83:803-819 (Pubitemid 36841911)
14. Akiyama F, Iwase H (2009) Triple negative breast cancer: clinicopathological characteristics and treatment strategies. Breast Cancer 16:252-253
15. Iwase H, Kurebayashi J, Tsuda H et al (2009) Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer 17:118-124
16. Yin WJ, Lu JS, Di GH et al (2009) Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat 115:325-333
17. Bosch A, Eroles P, Zaragoza R et al (2010) Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 36:206-215
18. Dawson SJ, Provenzano E, Caldas C (2009) Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer 45(Suppl 1):27-40
19. Tischkowitz M, Brunet JS, Begin LR et al (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7:134
20. Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652-5657 (Pubitemid 46631305)
21. Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triplenegative breast cancer. J Clin Oncol 26:1275-1281
22. Finn RS, Dering J, Ginther C et al (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105:319-326 (Pubitemid 47596452)
23. Wakeling AE (2005) Inhibitors of growth factor signalling. Endocr Relat Cancer 12 (Suppl 1):S183-S187 (Pubitemid 41395425)
24. Hoadley KA, Weigman VJ, Fan C et al (2007) EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 8:258